nodes	percent_of_prediction	percent_of_DWPC	metapath
Ingenol Mebutate—PRKCD—hematopoietic system—hematologic cancer	0.0215	0.148	CbGeAlD
Ingenol Mebutate—PRKCD—gonad—hematologic cancer	0.0163	0.112	CbGeAlD
Ingenol Mebutate—PRKCD—blood—hematologic cancer	0.0142	0.0979	CbGeAlD
Ingenol Mebutate—PRKCD—bone marrow—hematologic cancer	0.0138	0.0947	CbGeAlD
Ingenol Mebutate—PRKCD—lung—hematologic cancer	0.0125	0.0858	CbGeAlD
Ingenol Mebutate—PRKCA—hematopoietic system—hematologic cancer	0.0118	0.0815	CbGeAlD
Ingenol Mebutate—PRKCD—testis—hematologic cancer	0.0118	0.081	CbGeAlD
Ingenol Mebutate—PRKCA—gonad—hematologic cancer	0.00901	0.0619	CbGeAlD
Ingenol Mebutate—PRKCD—lymph node—hematologic cancer	0.00853	0.0587	CbGeAlD
Ingenol Mebutate—PRKCA—blood—hematologic cancer	0.00785	0.054	CbGeAlD
Ingenol Mebutate—PRKCA—lung—hematologic cancer	0.00688	0.0473	CbGeAlD
Ingenol Mebutate—PRKCA—testis—hematologic cancer	0.00649	0.0446	CbGeAlD
Ingenol Mebutate—PRKCA—lymph node—hematologic cancer	0.0047	0.0324	CbGeAlD
Ingenol Mebutate—PRKCD—Azacitidine—Pentostatin—hematologic cancer	0.0021	0.192	CbGdCrCtD
Ingenol Mebutate—PRKCD—Azacitidine—Clofarabine—hematologic cancer	0.00187	0.171	CbGdCrCtD
Ingenol Mebutate—PRKCD—Azacitidine—Nelarabine—hematologic cancer	0.00176	0.16	CbGdCrCtD
Ingenol Mebutate—PRKCD—Azacitidine—Fludarabine—hematologic cancer	0.00137	0.125	CbGdCrCtD
Ingenol Mebutate—PRKCD—Azacitidine—Cytarabine—hematologic cancer	0.00129	0.118	CbGdCrCtD
Ingenol Mebutate—PRKCD—Azacitidine—Gemcitabine—hematologic cancer	0.00129	0.118	CbGdCrCtD
Ingenol Mebutate—PRKCD—Azacitidine—Cladribine—hematologic cancer	0.00126	0.115	CbGdCrCtD
Ingenol Mebutate—Ulcer—Irinotecan—hematologic cancer	0.00118	0.00501	CcSEcCtD
Ingenol Mebutate—Ulcer—Mitoxantrone—hematologic cancer	0.00118	0.00501	CcSEcCtD
Ingenol Mebutate—Ulcer—Gemcitabine—hematologic cancer	0.00115	0.00488	CcSEcCtD
Ingenol Mebutate—Eye disorder—Nelarabine—hematologic cancer	0.00114	0.00487	CcSEcCtD
Ingenol Mebutate—Nasopharyngitis—Nilotinib—hematologic cancer	0.00113	0.00479	CcSEcCtD
Ingenol Mebutate—Nasopharyngitis—Imatinib—hematologic cancer	0.00112	0.00476	CcSEcCtD
Ingenol Mebutate—Eye pain—Bortezomib—hematologic cancer	0.00111	0.00473	CcSEcCtD
Ingenol Mebutate—Infestation NOS—Busulfan—hematologic cancer	0.0011	0.0047	CcSEcCtD
Ingenol Mebutate—Infestation—Busulfan—hematologic cancer	0.0011	0.0047	CcSEcCtD
Ingenol Mebutate—Ulcer—Cisplatin—hematologic cancer	0.00107	0.00455	CcSEcCtD
Ingenol Mebutate—Infection—Lomustine—hematologic cancer	0.00107	0.00455	CcSEcCtD
Ingenol Mebutate—Eye disorder—Anagrelide—hematologic cancer	0.00107	0.00453	CcSEcCtD
Ingenol Mebutate—Infestation NOS—Dasatinib—hematologic cancer	0.00105	0.00447	CcSEcCtD
Ingenol Mebutate—Infestation—Dasatinib—hematologic cancer	0.00105	0.00447	CcSEcCtD
Ingenol Mebutate—Erythema—Methoxsalen—hematologic cancer	0.00104	0.00443	CcSEcCtD
Ingenol Mebutate—Infection—Mechlorethamine—hematologic cancer	0.00102	0.00436	CcSEcCtD
Ingenol Mebutate—Conjunctivitis—Bexarotene—hematologic cancer	0.00102	0.00434	CcSEcCtD
Ingenol Mebutate—Conjunctivitis—Dasatinib—hematologic cancer	0.00102	0.00434	CcSEcCtD
Ingenol Mebutate—Eye pain—Thalidomide—hematologic cancer	0.001	0.00427	CcSEcCtD
Ingenol Mebutate—Erythema—Clofarabine—hematologic cancer	0.000997	0.00424	CcSEcCtD
Ingenol Mebutate—Erythema—Daunorubicin—hematologic cancer	0.000997	0.00424	CcSEcCtD
Ingenol Mebutate—Swelling—Carmustine—hematologic cancer	0.000986	0.00419	CcSEcCtD
Ingenol Mebutate—Ulcer—Etoposide—hematologic cancer	0.00098	0.00417	CcSEcCtD
Ingenol Mebutate—Swelling—Alitretinoin—hematologic cancer	0.000977	0.00415	CcSEcCtD
Ingenol Mebutate—Nasopharyngitis—Lenalidomide—hematologic cancer	0.000976	0.00415	CcSEcCtD
Ingenol Mebutate—Infestation NOS—Nilotinib—hematologic cancer	0.000971	0.00413	CcSEcCtD
Ingenol Mebutate—Infestation—Nilotinib—hematologic cancer	0.000971	0.00413	CcSEcCtD
Ingenol Mebutate—Swelling—Ifosfamide—hematologic cancer	0.000966	0.00411	CcSEcCtD
Ingenol Mebutate—Infestation—Imatinib—hematologic cancer	0.000965	0.0041	CcSEcCtD
Ingenol Mebutate—Infestation NOS—Imatinib—hematologic cancer	0.000965	0.0041	CcSEcCtD
Ingenol Mebutate—Eye pain—Carmustine—hematologic cancer	0.000964	0.0041	CcSEcCtD
Ingenol Mebutate—Infestation NOS—Cladribine—hematologic cancer	0.000948	0.00403	CcSEcCtD
Ingenol Mebutate—Infestation—Cladribine—hematologic cancer	0.000948	0.00403	CcSEcCtD
Ingenol Mebutate—Conjunctivitis—Nilotinib—hematologic cancer	0.000943	0.00401	CcSEcCtD
Ingenol Mebutate—Conjunctivitis—Imatinib—hematologic cancer	0.000938	0.00399	CcSEcCtD
Ingenol Mebutate—Eye disorder—Busulfan—hematologic cancer	0.000927	0.00394	CcSEcCtD
Ingenol Mebutate—Conjunctivitis—Cladribine—hematologic cancer	0.000922	0.00392	CcSEcCtD
Ingenol Mebutate—Swelling—Mitoxantrone—hematologic cancer	0.000917	0.0039	CcSEcCtD
Ingenol Mebutate—Nasopharyngitis—Bortezomib—hematologic cancer	0.000898	0.00382	CcSEcCtD
Ingenol Mebutate—Headache—Ruxolitinib—hematologic cancer	0.00089	0.00378	CcSEcCtD
Ingenol Mebutate—Ulcer—Triamcinolone—hematologic cancer	0.000889	0.00378	CcSEcCtD
Ingenol Mebutate—Eye disorder—Bexarotene—hematologic cancer	0.000881	0.00375	CcSEcCtD
Ingenol Mebutate—Eye disorder—Dasatinib—hematologic cancer	0.000881	0.00375	CcSEcCtD
Ingenol Mebutate—Infection—Nelarabine—hematologic cancer	0.000864	0.00367	CcSEcCtD
Ingenol Mebutate—Erythema—Busulfan—hematologic cancer	0.000863	0.00367	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Nelarabine—hematologic cancer	0.000853	0.00363	CcSEcCtD
Ingenol Mebutate—Infection—Methoxsalen—hematologic cancer	0.000844	0.00359	CcSEcCtD
Ingenol Mebutate—Infestation NOS—Lenalidomide—hematologic cancer	0.000841	0.00358	CcSEcCtD
Ingenol Mebutate—Infestation—Lenalidomide—hematologic cancer	0.000841	0.00358	CcSEcCtD
Ingenol Mebutate—Infestation NOS—Hydroxyurea—hematologic cancer	0.000829	0.00353	CcSEcCtD
Ingenol Mebutate—Infestation—Hydroxyurea—hematologic cancer	0.000829	0.00353	CcSEcCtD
Ingenol Mebutate—Erythema—Bexarotene—hematologic cancer	0.000821	0.00349	CcSEcCtD
Ingenol Mebutate—Erythema—Dasatinib—hematologic cancer	0.000821	0.00349	CcSEcCtD
Ingenol Mebutate—Conjunctivitis—Lenalidomide—hematologic cancer	0.000818	0.00348	CcSEcCtD
Ingenol Mebutate—Eye disorder—Nilotinib—hematologic cancer	0.000814	0.00346	CcSEcCtD
Ingenol Mebutate—Eye disorder—Imatinib—hematologic cancer	0.00081	0.00344	CcSEcCtD
Ingenol Mebutate—Infection—Daunorubicin—hematologic cancer	0.000809	0.00344	CcSEcCtD
Ingenol Mebutate—Infection—Clofarabine—hematologic cancer	0.000809	0.00344	CcSEcCtD
Ingenol Mebutate—Ulcer—Dexamethasone—hematologic cancer	0.000806	0.00343	CcSEcCtD
Ingenol Mebutate—Ulcer—Betamethasone—hematologic cancer	0.000806	0.00343	CcSEcCtD
Ingenol Mebutate—Infection—Anagrelide—hematologic cancer	0.000805	0.00342	CcSEcCtD
Ingenol Mebutate—Infection—Pentostatin—hematologic cancer	0.000805	0.00342	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Clofarabine—hematologic cancer	0.000798	0.00339	CcSEcCtD
Ingenol Mebutate—Eye disorder—Cladribine—hematologic cancer	0.000796	0.00338	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Pentostatin—hematologic cancer	0.000795	0.00338	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Anagrelide—hematologic cancer	0.000795	0.00338	CcSEcCtD
Ingenol Mebutate—Infection—Idarubicin—hematologic cancer	0.000776	0.0033	CcSEcCtD
Ingenol Mebutate—Infestation NOS—Bortezomib—hematologic cancer	0.000774	0.00329	CcSEcCtD
Ingenol Mebutate—Infestation—Bortezomib—hematologic cancer	0.000774	0.00329	CcSEcCtD
Ingenol Mebutate—Nasopharyngitis—Alitretinoin—hematologic cancer	0.000771	0.00328	CcSEcCtD
Ingenol Mebutate—Swelling—Etoposide—hematologic cancer	0.000763	0.00324	CcSEcCtD
Ingenol Mebutate—Erythema—Nilotinib—hematologic cancer	0.000758	0.00323	CcSEcCtD
Ingenol Mebutate—Infestation—Vinorelbine—hematologic cancer	0.000756	0.00321	CcSEcCtD
Ingenol Mebutate—Infestation NOS—Vinorelbine—hematologic cancer	0.000756	0.00321	CcSEcCtD
Ingenol Mebutate—Infection—Teniposide—hematologic cancer	0.000755	0.00321	CcSEcCtD
Ingenol Mebutate—Erythema—Imatinib—hematologic cancer	0.000754	0.00321	CcSEcCtD
Ingenol Mebutate—Conjunctivitis—Bortezomib—hematologic cancer	0.000752	0.0032	CcSEcCtD
Ingenol Mebutate—Headache—Vorinostat—hematologic cancer	0.000752	0.0032	CcSEcCtD
Ingenol Mebutate—Erythema—Cladribine—hematologic cancer	0.000741	0.00315	CcSEcCtD
Ingenol Mebutate—Infestation NOS—Thiotepa—hematologic cancer	0.000722	0.00307	CcSEcCtD
Ingenol Mebutate—Infestation—Thiotepa—hematologic cancer	0.000722	0.00307	CcSEcCtD
Ingenol Mebutate—Eye disorder—Lenalidomide—hematologic cancer	0.000706	0.003	CcSEcCtD
Ingenol Mebutate—Ulcer—Prednisone—hematologic cancer	0.000702	0.00299	CcSEcCtD
Ingenol Mebutate—Conjunctivitis—Thiotepa—hematologic cancer	0.000702	0.00298	CcSEcCtD
Ingenol Mebutate—Infection—Busulfan—hematologic cancer	0.0007	0.00298	CcSEcCtD
Ingenol Mebutate—Infestation NOS—Thalidomide—hematologic cancer	0.000698	0.00297	CcSEcCtD
Ingenol Mebutate—Infestation—Thalidomide—hematologic cancer	0.000698	0.00297	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Busulfan—hematologic cancer	0.000691	0.00294	CcSEcCtD
Ingenol Mebutate—Infection—Procarbazine—hematologic cancer	0.000679	0.00289	CcSEcCtD
Ingenol Mebutate—Conjunctivitis—Thalidomide—hematologic cancer	0.000679	0.00289	CcSEcCtD
Ingenol Mebutate—Infection—Bexarotene—hematologic cancer	0.000666	0.00283	CcSEcCtD
Ingenol Mebutate—Infection—Dasatinib—hematologic cancer	0.000666	0.00283	CcSEcCtD
Ingenol Mebutate—Infestation NOS—Alitretinoin—hematologic cancer	0.000664	0.00282	CcSEcCtD
Ingenol Mebutate—Infestation—Alitretinoin—hematologic cancer	0.000664	0.00282	CcSEcCtD
Ingenol Mebutate—Infection—Fludarabine—hematologic cancer	0.000664	0.00282	CcSEcCtD
Ingenol Mebutate—Erythema—Lenalidomide—hematologic cancer	0.000657	0.0028	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Bexarotene—hematologic cancer	0.000657	0.00279	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Dasatinib—hematologic cancer	0.000657	0.00279	CcSEcCtD
Ingenol Mebutate—Nasopharyngitis—Cisplatin—hematologic cancer	0.000657	0.00279	CcSEcCtD
Ingenol Mebutate—Infestation NOS—Ifosfamide—hematologic cancer	0.000656	0.00279	CcSEcCtD
Ingenol Mebutate—Infestation—Ifosfamide—hematologic cancer	0.000656	0.00279	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Fludarabine—hematologic cancer	0.000655	0.00279	CcSEcCtD
Ingenol Mebutate—Eye disorder—Bortezomib—hematologic cancer	0.000649	0.00276	CcSEcCtD
Ingenol Mebutate—Erythema—Hydroxyurea—hematologic cancer	0.000648	0.00276	CcSEcCtD
Ingenol Mebutate—Conjunctivitis—Alitretinoin—hematologic cancer	0.000646	0.00275	CcSEcCtD
Ingenol Mebutate—Conjunctivitis—Ifosfamide—hematologic cancer	0.000638	0.00271	CcSEcCtD
Ingenol Mebutate—Infection—Chlorambucil—hematologic cancer	0.000629	0.00267	CcSEcCtD
Ingenol Mebutate—Infection—Nilotinib—hematologic cancer	0.000615	0.00262	CcSEcCtD
Ingenol Mebutate—Eye pain—Dexamethasone—hematologic cancer	0.000613	0.00261	CcSEcCtD
Ingenol Mebutate—Eye pain—Betamethasone—hematologic cancer	0.000613	0.00261	CcSEcCtD
Ingenol Mebutate—Infection—Imatinib—hematologic cancer	0.000612	0.0026	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Nilotinib—hematologic cancer	0.000607	0.00258	CcSEcCtD
Ingenol Mebutate—Conjunctivitis—Mitoxantrone—hematologic cancer	0.000606	0.00258	CcSEcCtD
Ingenol Mebutate—Eye disorder—Thiotepa—hematologic cancer	0.000606	0.00258	CcSEcCtD
Ingenol Mebutate—Erythema—Bortezomib—hematologic cancer	0.000605	0.00257	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Imatinib—hematologic cancer	0.000604	0.00257	CcSEcCtD
Ingenol Mebutate—Infection—Cladribine—hematologic cancer	0.000601	0.00256	CcSEcCtD
Ingenol Mebutate—Erythema—Bleomycin—hematologic cancer	0.0006	0.00255	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Cladribine—hematologic cancer	0.000593	0.00252	CcSEcCtD
Ingenol Mebutate—Erythema—Vinorelbine—hematologic cancer	0.000591	0.00251	CcSEcCtD
Ingenol Mebutate—Ulcer—Methotrexate—hematologic cancer	0.000587	0.0025	CcSEcCtD
Ingenol Mebutate—Eye disorder—Thalidomide—hematologic cancer	0.000586	0.00249	CcSEcCtD
Ingenol Mebutate—Erythema—Thiotepa—hematologic cancer	0.000564	0.0024	CcSEcCtD
Ingenol Mebutate—Eye disorder—Carmustine—hematologic cancer	0.000562	0.00239	CcSEcCtD
Ingenol Mebutate—Eye disorder—Alitretinoin—hematologic cancer	0.000557	0.00237	CcSEcCtD
Ingenol Mebutate—Eye disorder—Ifosfamide—hematologic cancer	0.000551	0.00234	CcSEcCtD
Ingenol Mebutate—Conjunctivitis—Cisplatin—hematologic cancer	0.00055	0.00234	CcSEcCtD
Ingenol Mebutate—Ulcer—Epirubicin—hematologic cancer	0.000549	0.00234	CcSEcCtD
Ingenol Mebutate—Infection—Melphalan—hematologic cancer	0.000548	0.00233	CcSEcCtD
Ingenol Mebutate—Headache—Nelarabine—hematologic cancer	0.000545	0.00232	CcSEcCtD
Ingenol Mebutate—Infection—Lenalidomide—hematologic cancer	0.000533	0.00227	CcSEcCtD
Ingenol Mebutate—Headache—Methoxsalen—hematologic cancer	0.000532	0.00226	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Lenalidomide—hematologic cancer	0.000526	0.00224	CcSEcCtD
Ingenol Mebutate—Infection—Hydroxyurea—hematologic cancer	0.000526	0.00223	CcSEcCtD
Ingenol Mebutate—Erythema—Carmustine—hematologic cancer	0.000524	0.00223	CcSEcCtD
Ingenol Mebutate—Erythema—Alitretinoin—hematologic cancer	0.000519	0.00221	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Hydroxyurea—hematologic cancer	0.000519	0.00221	CcSEcCtD
Ingenol Mebutate—Infestation—Etoposide—hematologic cancer	0.000518	0.0022	CcSEcCtD
Ingenol Mebutate—Infestation NOS—Etoposide—hematologic cancer	0.000518	0.0022	CcSEcCtD
Ingenol Mebutate—Erythema—Ifosfamide—hematologic cancer	0.000513	0.00218	CcSEcCtD
Ingenol Mebutate—Headache—Clofarabine—hematologic cancer	0.00051	0.00217	CcSEcCtD
Ingenol Mebutate—Headache—Daunorubicin—hematologic cancer	0.00051	0.00217	CcSEcCtD
Ingenol Mebutate—Ulcer—Doxorubicin—hematologic cancer	0.000508	0.00216	CcSEcCtD
Ingenol Mebutate—Headache—Anagrelide—hematologic cancer	0.000508	0.00216	CcSEcCtD
Ingenol Mebutate—Headache—Pentostatin—hematologic cancer	0.000508	0.00216	CcSEcCtD
Ingenol Mebutate—Conjunctivitis—Prednisolone—hematologic cancer	0.000497	0.00211	CcSEcCtD
Ingenol Mebutate—Infection—Bortezomib—hematologic cancer	0.00049	0.00209	CcSEcCtD
Ingenol Mebutate—Headache—Idarubicin—hematologic cancer	0.00049	0.00208	CcSEcCtD
Ingenol Mebutate—Erythema—Mitoxantrone—hematologic cancer	0.000487	0.00207	CcSEcCtD
Ingenol Mebutate—Infection—Bleomycin—hematologic cancer	0.000487	0.00207	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Bortezomib—hematologic cancer	0.000484	0.00206	CcSEcCtD
Ingenol Mebutate—Infection—Vinorelbine—hematologic cancer	0.000479	0.00204	CcSEcCtD
Ingenol Mebutate—Headache—Teniposide—hematologic cancer	0.000476	0.00203	CcSEcCtD
Ingenol Mebutate—Eye disorder—Cisplatin—hematologic cancer	0.000475	0.00202	CcSEcCtD
Ingenol Mebutate—Erythema—Gemcitabine—hematologic cancer	0.000474	0.00202	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Vinorelbine—hematologic cancer	0.000473	0.00201	CcSEcCtD
Ingenol Mebutate—Infection—Thiotepa—hematologic cancer	0.000457	0.00194	CcSEcCtD
Ingenol Mebutate—Conjunctivitis—Triamcinolone—hematologic cancer	0.000457	0.00194	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Thiotepa—hematologic cancer	0.000451	0.00192	CcSEcCtD
Ingenol Mebutate—Infection—Thalidomide—hematologic cancer	0.000442	0.00188	CcSEcCtD
Ingenol Mebutate—Erythema—Cisplatin—hematologic cancer	0.000442	0.00188	CcSEcCtD
Ingenol Mebutate—Headache—Busulfan—hematologic cancer	0.000441	0.00188	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Thalidomide—hematologic cancer	0.000437	0.00186	CcSEcCtD
Ingenol Mebutate—Eye disorder—Etoposide—hematologic cancer	0.000435	0.00185	CcSEcCtD
Ingenol Mebutate—Headache—Procarbazine—hematologic cancer	0.000428	0.00182	CcSEcCtD
Ingenol Mebutate—Infection—Carmustine—hematologic cancer	0.000425	0.00181	CcSEcCtD
Ingenol Mebutate—Infection—Alitretinoin—hematologic cancer	0.000421	0.00179	CcSEcCtD
Ingenol Mebutate—Headache—Dasatinib—hematologic cancer	0.00042	0.00178	CcSEcCtD
Ingenol Mebutate—Headache—Bexarotene—hematologic cancer	0.00042	0.00178	CcSEcCtD
Ingenol Mebutate—Headache—Fludarabine—hematologic cancer	0.000419	0.00178	CcSEcCtD
Ingenol Mebutate—Eye pain—Epirubicin—hematologic cancer	0.000418	0.00178	CcSEcCtD
Ingenol Mebutate—Infection—Ifosfamide—hematologic cancer	0.000416	0.00177	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Alitretinoin—hematologic cancer	0.000415	0.00177	CcSEcCtD
Ingenol Mebutate—Conjunctivitis—Dexamethasone—hematologic cancer	0.000415	0.00176	CcSEcCtD
Ingenol Mebutate—Conjunctivitis—Betamethasone—hematologic cancer	0.000415	0.00176	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Ifosfamide—hematologic cancer	0.000411	0.00175	CcSEcCtD
Ingenol Mebutate—Infection—Vincristine—hematologic cancer	0.000406	0.00172	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Vincristine—hematologic cancer	0.0004	0.0017	CcSEcCtD
Ingenol Mebutate—Erythema—Prednisolone—hematologic cancer	0.0004	0.0017	CcSEcCtD
Ingenol Mebutate—Infection—Mitoxantrone—hematologic cancer	0.000395	0.00168	CcSEcCtD
Ingenol Mebutate—Infection—Irinotecan—hematologic cancer	0.000395	0.00168	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Irinotecan—hematologic cancer	0.00039	0.00166	CcSEcCtD
Ingenol Mebutate—Headache—Nilotinib—hematologic cancer	0.000388	0.00165	CcSEcCtD
Ingenol Mebutate—Eye pain—Doxorubicin—hematologic cancer	0.000387	0.00164	CcSEcCtD
Ingenol Mebutate—Headache—Imatinib—hematologic cancer	0.000386	0.00164	CcSEcCtD
Ingenol Mebutate—Infection—Gemcitabine—hematologic cancer	0.000385	0.00164	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Gemcitabine—hematologic cancer	0.00038	0.00162	CcSEcCtD
Ingenol Mebutate—Headache—Cladribine—hematologic cancer	0.000379	0.00161	CcSEcCtD
Ingenol Mebutate—Erythema—Triamcinolone—hematologic cancer	0.000368	0.00156	CcSEcCtD
Ingenol Mebutate—Headache—Vinblastine—hematologic cancer	0.000363	0.00155	CcSEcCtD
Ingenol Mebutate—Infection—Cisplatin—hematologic cancer	0.000359	0.00152	CcSEcCtD
Ingenol Mebutate—Eye disorder—Dexamethasone—hematologic cancer	0.000358	0.00152	CcSEcCtD
Ingenol Mebutate—Eye disorder—Betamethasone—hematologic cancer	0.000358	0.00152	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Cisplatin—hematologic cancer	0.000354	0.00151	CcSEcCtD
Ingenol Mebutate—Nasopharyngitis—Epirubicin—hematologic cancer	0.000337	0.00143	CcSEcCtD
Ingenol Mebutate—Headache—Lenalidomide—hematologic cancer	0.000336	0.00143	CcSEcCtD
Ingenol Mebutate—Erythema—Dexamethasone—hematologic cancer	0.000333	0.00142	CcSEcCtD
Ingenol Mebutate—Erythema—Betamethasone—hematologic cancer	0.000333	0.00142	CcSEcCtD
Ingenol Mebutate—Headache—Hydroxyurea—hematologic cancer	0.000331	0.00141	CcSEcCtD
Ingenol Mebutate—Infection—Etoposide—hematologic cancer	0.000329	0.0014	CcSEcCtD
Ingenol Mebutate—Nasopharyngitis—Doxorubicin—hematologic cancer	0.000312	0.00133	CcSEcCtD
Ingenol Mebutate—Eye disorder—Prednisone—hematologic cancer	0.000312	0.00133	CcSEcCtD
Ingenol Mebutate—Infestation NOS—Methotrexate—hematologic cancer	0.000311	0.00132	CcSEcCtD
Ingenol Mebutate—Infestation—Methotrexate—hematologic cancer	0.000311	0.00132	CcSEcCtD
Ingenol Mebutate—Headache—Bortezomib—hematologic cancer	0.000309	0.00132	CcSEcCtD
Ingenol Mebutate—Headache—Vinorelbine—hematologic cancer	0.000302	0.00128	CcSEcCtD
Ingenol Mebutate—Conjunctivitis—Methotrexate—hematologic cancer	0.000302	0.00128	CcSEcCtD
Ingenol Mebutate—Infection—Triamcinolone—hematologic cancer	0.000298	0.00127	CcSEcCtD
Ingenol Mebutate—Infestation NOS—Epirubicin—hematologic cancer	0.000291	0.00124	CcSEcCtD
Ingenol Mebutate—Infestation—Epirubicin—hematologic cancer	0.000291	0.00124	CcSEcCtD
Ingenol Mebutate—Erythema—Prednisone—hematologic cancer	0.00029	0.00123	CcSEcCtD
Ingenol Mebutate—Headache—Thiotepa—hematologic cancer	0.000288	0.00123	CcSEcCtD
Ingenol Mebutate—Conjunctivitis—Epirubicin—hematologic cancer	0.000283	0.0012	CcSEcCtD
Ingenol Mebutate—Headache—Thalidomide—hematologic cancer	0.000279	0.00119	CcSEcCtD
Ingenol Mebutate—Infection—Betamethasone—hematologic cancer	0.00027	0.00115	CcSEcCtD
Ingenol Mebutate—Infection—Dexamethasone—hematologic cancer	0.00027	0.00115	CcSEcCtD
Ingenol Mebutate—Infestation NOS—Doxorubicin—hematologic cancer	0.000269	0.00114	CcSEcCtD
Ingenol Mebutate—Infestation—Doxorubicin—hematologic cancer	0.000269	0.00114	CcSEcCtD
Ingenol Mebutate—Headache—Carmustine—hematologic cancer	0.000268	0.00114	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Betamethasone—hematologic cancer	0.000267	0.00113	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Dexamethasone—hematologic cancer	0.000267	0.00113	CcSEcCtD
Ingenol Mebutate—Headache—Alitretinoin—hematologic cancer	0.000265	0.00113	CcSEcCtD
Ingenol Mebutate—Conjunctivitis—Doxorubicin—hematologic cancer	0.000261	0.00111	CcSEcCtD
Ingenol Mebutate—Eye disorder—Methotrexate—hematologic cancer	0.000261	0.00111	CcSEcCtD
Ingenol Mebutate—Headache—Vincristine—hematologic cancer	0.000256	0.00109	CcSEcCtD
Ingenol Mebutate—Headache—Mitoxantrone—hematologic cancer	0.000249	0.00106	CcSEcCtD
Ingenol Mebutate—Headache—Irinotecan—hematologic cancer	0.000249	0.00106	CcSEcCtD
Ingenol Mebutate—Eye disorder—Epirubicin—hematologic cancer	0.000244	0.00104	CcSEcCtD
Ingenol Mebutate—Erythema—Methotrexate—hematologic cancer	0.000243	0.00103	CcSEcCtD
Ingenol Mebutate—Headache—Gemcitabine—hematologic cancer	0.000243	0.00103	CcSEcCtD
Ingenol Mebutate—Infection—Prednisone—hematologic cancer	0.000235	0.001	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Prednisone—hematologic cancer	0.000232	0.000988	CcSEcCtD
Ingenol Mebutate—Erythema—Epirubicin—hematologic cancer	0.000227	0.000966	CcSEcCtD
Ingenol Mebutate—Eye disorder—Doxorubicin—hematologic cancer	0.000226	0.000959	CcSEcCtD
Ingenol Mebutate—Erythema—Doxorubicin—hematologic cancer	0.00021	0.000894	CcSEcCtD
Ingenol Mebutate—Headache—Etoposide—hematologic cancer	0.000207	0.000881	CcSEcCtD
Ingenol Mebutate—Headache—Prednisolone—hematologic cancer	0.000204	0.000869	CcSEcCtD
Ingenol Mebutate—Infection—Methotrexate—hematologic cancer	0.000197	0.000837	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Methotrexate—hematologic cancer	0.000194	0.000826	CcSEcCtD
Ingenol Mebutate—Headache—Triamcinolone—hematologic cancer	0.000188	0.000799	CcSEcCtD
Ingenol Mebutate—Infection—Epirubicin—hematologic cancer	0.000184	0.000783	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Epirubicin—hematologic cancer	0.000182	0.000773	CcSEcCtD
Ingenol Mebutate—Headache—Betamethasone—hematologic cancer	0.00017	0.000725	CcSEcCtD
Ingenol Mebutate—Headache—Dexamethasone—hematologic cancer	0.00017	0.000725	CcSEcCtD
Ingenol Mebutate—Infection—Doxorubicin—hematologic cancer	0.00017	0.000725	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Doxorubicin—hematologic cancer	0.000168	0.000715	CcSEcCtD
Ingenol Mebutate—Headache—Prednisone—hematologic cancer	0.000148	0.000631	CcSEcCtD
Ingenol Mebutate—Headache—Methotrexate—hematologic cancer	0.000124	0.000528	CcSEcCtD
Ingenol Mebutate—Headache—Epirubicin—hematologic cancer	0.000116	0.000494	CcSEcCtD
Ingenol Mebutate—Headache—Doxorubicin—hematologic cancer	0.000107	0.000457	CcSEcCtD
Ingenol Mebutate—PRKCA—Immune System—BAD—hematologic cancer	1.34e-05	2.2e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—NFKBIA—hematologic cancer	1.34e-05	2.2e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Immune System—STAT3—hematologic cancer	1.34e-05	2.2e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—STAT1—hematologic cancer	1.34e-05	2.2e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Immune System—NRAS—hematologic cancer	1.34e-05	2.2e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by GPCR—CCL2—hematologic cancer	1.32e-05	2.18e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Cell Cycle—MAPK3—hematologic cancer	1.32e-05	2.17e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Gene Expression—NOTCH1—hematologic cancer	1.32e-05	2.17e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by GPCR—IL6R—hematologic cancer	1.32e-05	2.17e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Disease—EP300—hematologic cancer	1.32e-05	2.17e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Innate Immune System—NRAS—hematologic cancer	1.32e-05	2.17e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—FGFR3—hematologic cancer	1.31e-05	2.15e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—CD80—hematologic cancer	1.3e-05	2.14e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—GPCR downstream signaling—PIK3R1—hematologic cancer	1.3e-05	2.14e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—KIT—hematologic cancer	1.3e-05	2.13e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—MAP2K1—hematologic cancer	1.29e-05	2.13e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Cell Cycle—MYC—hematologic cancer	1.29e-05	2.11e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—PIK3CD—hematologic cancer	1.29e-05	2.11e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Disease—SRC—hematologic cancer	1.28e-05	2.11e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Immune System—MAPK3—hematologic cancer	1.28e-05	2.1e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—PTPN11—hematologic cancer	1.28e-05	2.1e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—GPCR downstream signaling—PIK3CA—hematologic cancer	1.27e-05	2.09e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Gene Expression—MAPK3—hematologic cancer	1.27e-05	2.09e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—GPCR downstream signaling—JAK2—hematologic cancer	1.26e-05	2.08e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Innate Immune System—MAPK3—hematologic cancer	1.26e-05	2.07e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Hemostasis—KRAS—hematologic cancer	1.26e-05	2.07e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling by GPCR—KRAS—hematologic cancer	1.26e-05	2.07e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by GPCR—MAP2K1—hematologic cancer	1.26e-05	2.07e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—GRB2—hematologic cancer	1.25e-05	2.06e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by GPCR—PIK3CD—hematologic cancer	1.25e-05	2.05e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—PDGFA—hematologic cancer	1.25e-05	2.05e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—FOS—hematologic cancer	1.24e-05	2.04e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—BAD—hematologic cancer	1.24e-05	2.04e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Gene Expression—MYC—hematologic cancer	1.24e-05	2.03e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Disease—STAT3—hematologic cancer	1.24e-05	2.03e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—CREB1—hematologic cancer	1.24e-05	2.03e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Disease—NRAS—hematologic cancer	1.23e-05	2.03e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—KITLG—hematologic cancer	1.23e-05	2.02e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—FGF2—hematologic cancer	1.23e-05	2.02e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—NOTCH1—hematologic cancer	1.23e-05	2.02e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—PIK3R1—hematologic cancer	1.21e-05	2e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—CASP8—hematologic cancer	1.21e-05	1.99e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—IL6R—hematologic cancer	1.21e-05	1.98e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—CREBBP—hematologic cancer	1.2e-05	1.98e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—STAT5A—hematologic cancer	1.2e-05	1.98e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—CD80—hematologic cancer	1.2e-05	1.97e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—GPCR downstream signaling—PIK3CB—hematologic cancer	1.2e-05	1.97e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—KIT—hematologic cancer	1.2e-05	1.97e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Gene Expression—CREBBP—hematologic cancer	1.2e-05	1.97e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Metabolism—MTHFR—hematologic cancer	1.2e-05	1.96e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—CDKN2B—hematologic cancer	1.19e-05	1.96e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Disease—MAPK3—hematologic cancer	1.18e-05	1.94e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by GPCR—PIK3R1—hematologic cancer	1.18e-05	1.94e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—JAK2—hematologic cancer	1.18e-05	1.94e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—PTPN11—hematologic cancer	1.18e-05	1.94e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Hemostasis—PIK3CA—hematologic cancer	1.16e-05	1.9e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling by GPCR—PIK3CA—hematologic cancer	1.16e-05	1.9e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—CD86—hematologic cancer	1.15e-05	1.9e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—MDM2—hematologic cancer	1.15e-05	1.89e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Immune System—KRAS—hematologic cancer	1.15e-05	1.89e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—MAP2K1—hematologic cancer	1.15e-05	1.89e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Disease—MYC—hematologic cancer	1.15e-05	1.89e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by GPCR—JAK2—hematologic cancer	1.15e-05	1.89e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Disease—TGFB1—hematologic cancer	1.15e-05	1.88e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—PIK3CD—hematologic cancer	1.14e-05	1.88e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—CREB1—hematologic cancer	1.14e-05	1.88e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—HES1—hematologic cancer	1.14e-05	1.87e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Innate Immune System—KRAS—hematologic cancer	1.13e-05	1.86e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—NCOR1—hematologic cancer	1.13e-05	1.86e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—BRAF—hematologic cancer	1.13e-05	1.85e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—PIK3CB—hematologic cancer	1.12e-05	1.84e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—MTOR—hematologic cancer	1.12e-05	1.84e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Hemostasis—TP53—hematologic cancer	1.12e-05	1.84e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—CSF2—hematologic cancer	1.12e-05	1.84e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—FGF1—hematologic cancer	1.12e-05	1.84e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—IL6R—hematologic cancer	1.11e-05	1.83e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—CREBBP—hematologic cancer	1.11e-05	1.83e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—FOXO1—hematologic cancer	1.1e-05	1.81e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—GPCR downstream signaling—IL2—hematologic cancer	1.1e-05	1.81e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—PDGFRB—hematologic cancer	1.1e-05	1.81e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—FGF2—hematologic cancer	1.09e-05	1.8e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by GPCR—PIK3CB—hematologic cancer	1.09e-05	1.79e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—PDGFRA—hematologic cancer	1.08e-05	1.78e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—PRKCG—hematologic cancer	1.08e-05	1.77e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—JAK1—hematologic cancer	1.08e-05	1.77e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—PIK3R1—hematologic cancer	1.08e-05	1.77e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Hemostasis—HRAS—hematologic cancer	1.07e-05	1.76e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling by GPCR—HRAS—hematologic cancer	1.07e-05	1.76e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Disease—KRAS—hematologic cancer	1.06e-05	1.74e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—MAP2K1—hematologic cancer	1.06e-05	1.74e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Immune System—PIK3CA—hematologic cancer	1.06e-05	1.74e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Cell Cycle—TP53—hematologic cancer	1.06e-05	1.74e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—PIK3CD—hematologic cancer	1.05e-05	1.73e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—CDKN1B—hematologic cancer	1.05e-05	1.73e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—JAK2—hematologic cancer	1.05e-05	1.72e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Innate Immune System—PIK3CA—hematologic cancer	1.04e-05	1.71e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—GPCR downstream signaling—AKT1—hematologic cancer	1.04e-05	1.71e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—BCL2—hematologic cancer	1.04e-05	1.71e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—CASP3—hematologic cancer	1.03e-05	1.69e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—IL2—hematologic cancer	1.03e-05	1.69e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—IFNG—hematologic cancer	1.03e-05	1.69e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling by GPCR—IL6—hematologic cancer	1.02e-05	1.68e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—MDM2—hematologic cancer	1.02e-05	1.68e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—FGF2—hematologic cancer	1.01e-05	1.66e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—IL2RA—hematologic cancer	1.01e-05	1.66e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Metabolism—PIK3CG—hematologic cancer	1e-05	1.65e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—CCND1—hematologic cancer	1e-05	1.65e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—JUN—hematologic cancer	1e-05	1.65e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by GPCR—IL2—hematologic cancer	1e-05	1.64e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—TERT—hematologic cancer	9.97e-06	1.64e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—PIK3R1—hematologic cancer	9.96e-06	1.64e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—MTOR—hematologic cancer	9.96e-06	1.64e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—PIK3CB—hematologic cancer	9.96e-06	1.64e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—CD4—hematologic cancer	9.94e-06	1.63e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Immune System—HRAS—hematologic cancer	9.78e-06	1.61e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Disease—PIK3CA—hematologic cancer	9.76e-06	1.6e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—PDGFB—hematologic cancer	9.73e-06	1.6e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—CDKN1A—hematologic cancer	9.71e-06	1.59e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—PTEN—hematologic cancer	9.68e-06	1.59e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—JAK2—hematologic cancer	9.68e-06	1.59e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Innate Immune System—HRAS—hematologic cancer	9.64e-06	1.58e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—TSC2—hematologic cancer	9.51e-06	1.56e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—MAPK8—hematologic cancer	9.47e-06	1.56e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Hemostasis—AKT1—hematologic cancer	9.45e-06	1.55e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling by GPCR—AKT1—hematologic cancer	9.45e-06	1.55e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—MDM2—hematologic cancer	9.45e-06	1.55e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Immune System—IL6—hematologic cancer	9.36e-06	1.54e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—CDKN1B—hematologic cancer	9.34e-06	1.54e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Metabolism—CREBBP—hematologic cancer	9.31e-06	1.53e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—EP300—hematologic cancer	9.23e-06	1.52e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Innate Immune System—IL6—hematologic cancer	9.23e-06	1.52e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—MTOR—hematologic cancer	9.19e-06	1.51e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—PIK3CB—hematologic cancer	9.19e-06	1.51e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—IL1B—hematologic cancer	9.18e-06	1.51e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—CD4—hematologic cancer	9.17e-06	1.51e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—FGFR3—hematologic cancer	9.15e-06	1.5e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—IL2—hematologic cancer	9.14e-06	1.5e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—MAPK14—hematologic cancer	9.06e-06	1.49e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Disease—HRAS—hematologic cancer	9.03e-06	1.48e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—SRC—hematologic cancer	8.98e-06	1.48e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—JUN—hematologic cancer	8.89e-06	1.46e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—ESR1—hematologic cancer	8.89e-06	1.46e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Metabolism—PIK3CD—hematologic cancer	8.83e-06	1.45e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—FN1—hematologic cancer	8.78e-06	1.44e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—VEGFA—hematologic cancer	8.75e-06	1.44e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Metabolism—ALB—hematologic cancer	8.72e-06	1.43e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—BAD—hematologic cancer	8.67e-06	1.43e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—NFKBIA—hematologic cancer	8.67e-06	1.43e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—STAT3—hematologic cancer	8.66e-06	1.42e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—NRAS—hematologic cancer	8.64e-06	1.42e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Disease—IL6—hematologic cancer	8.64e-06	1.42e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Immune System—AKT1—hematologic cancer	8.63e-06	1.42e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—CDKN1B—hematologic cancer	8.63e-06	1.42e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—CDKN1A—hematologic cancer	8.62e-06	1.42e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—PTEN—hematologic cancer	8.6e-06	1.41e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—NOTCH1—hematologic cancer	8.59e-06	1.41e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Gene Expression—AKT1—hematologic cancer	8.58e-06	1.41e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Innate Immune System—AKT1—hematologic cancer	8.51e-06	1.4e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—MAPK8—hematologic cancer	8.42e-06	1.38e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—CD80—hematologic cancer	8.42e-06	1.38e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—PIK3CG—hematologic cancer	8.4e-06	1.38e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—KIT—hematologic cancer	8.4e-06	1.38e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by GPCR—NRAS—hematologic cancer	8.4e-06	1.38e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Metabolism—PIK3R1—hematologic cancer	8.34e-06	1.37e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—MAPK3—hematologic cancer	8.27e-06	1.36e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—PTPN11—hematologic cancer	8.25e-06	1.36e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—EP300—hematologic cancer	8.2e-06	1.35e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—MYC—hematologic cancer	8.05e-06	1.32e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by GPCR—MAPK3—hematologic cancer	8.04e-06	1.32e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—TGFB1—hematologic cancer	8.03e-06	1.32e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—CREB1—hematologic cancer	8e-06	1.31e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—SRC—hematologic cancer	7.98e-06	1.31e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Disease—AKT1—hematologic cancer	7.97e-06	1.31e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—CDKN1A—hematologic cancer	7.96e-06	1.31e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—PTEN—hematologic cancer	7.94e-06	1.31e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—BRAF—hematologic cancer	7.9e-06	1.3e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—CCL2—hematologic cancer	7.82e-06	1.29e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—IL6R—hematologic cancer	7.8e-06	1.28e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—CREBBP—hematologic cancer	7.79e-06	1.28e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Metabolism—PIK3CB—hematologic cancer	7.7e-06	1.26e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—STAT3—hematologic cancer	7.69e-06	1.26e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—NRAS—hematologic cancer	7.67e-06	1.26e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—EP300—hematologic cancer	7.57e-06	1.24e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—KRAS—hematologic cancer	7.44e-06	1.22e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—MAP2K1—hematologic cancer	7.43e-06	1.22e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—PIK3CD—hematologic cancer	7.38e-06	1.21e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—SRC—hematologic cancer	7.37e-06	1.21e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—MAPK3—hematologic cancer	7.35e-06	1.21e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—GPCR downstream signaling—PIK3CA—hematologic cancer	7.31e-06	1.2e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Gene Expression—MAPK3—hematologic cancer	7.31e-06	1.2e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by GPCR—KRAS—hematologic cancer	7.23e-06	1.19e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Gene Expression—MYC—hematologic cancer	7.11e-06	1.17e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—STAT3—hematologic cancer	7.1e-06	1.17e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—NRAS—hematologic cancer	7.09e-06	1.16e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—FGF2—hematologic cancer	7.07e-06	1.16e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—PIK3R1—hematologic cancer	6.97e-06	1.15e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—PIK3CA—hematologic cancer	6.83e-06	1.12e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—MAPK3—hematologic cancer	6.79e-06	1.12e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—JAK2—hematologic cancer	6.78e-06	1.11e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Metabolism—PTEN—hematologic cancer	6.65e-06	1.09e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by GPCR—PIK3CA—hematologic cancer	6.64e-06	1.09e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—MDM2—hematologic cancer	6.62e-06	1.09e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—TP53—hematologic cancer	6.61e-06	1.09e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—KRAS—hematologic cancer	6.61e-06	1.09e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—MYC—hematologic cancer	6.6e-06	1.08e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—TGFB1—hematologic cancer	6.58e-06	1.08e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—PIK3CB—hematologic cancer	6.44e-06	1.06e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—MTOR—hematologic cancer	6.44e-06	1.06e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Metabolism—EP300—hematologic cancer	6.34e-06	1.04e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—HRAS—hematologic cancer	6.32e-06	1.04e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by GPCR—HRAS—hematologic cancer	6.15e-06	1.01e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—KRAS—hematologic cancer	6.1e-06	1e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—PIK3CA—hematologic cancer	6.07e-06	9.97e-06	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—IL6—hematologic cancer	6.05e-06	9.94e-06	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—CDKN1B—hematologic cancer	6.04e-06	9.93e-06	CbGpPWpGaD
Ingenol Mebutate—PRKCA—GPCR downstream signaling—AKT1—hematologic cancer	5.97e-06	9.82e-06	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—CASP3—hematologic cancer	5.92e-06	9.73e-06	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—IL2—hematologic cancer	5.91e-06	9.71e-06	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by GPCR—IL6—hematologic cancer	5.88e-06	9.66e-06	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—CCND1—hematologic cancer	5.76e-06	9.47e-06	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—JUN—hematologic cancer	5.75e-06	9.45e-06	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—HRAS—hematologic cancer	5.61e-06	9.23e-06	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—PIK3CA—hematologic cancer	5.6e-06	9.21e-06	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—AKT1—hematologic cancer	5.58e-06	9.17e-06	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—CDKN1A—hematologic cancer	5.57e-06	9.16e-06	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—PTEN—hematologic cancer	5.56e-06	9.14e-06	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—MAPK8—hematologic cancer	5.44e-06	8.94e-06	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by GPCR—AKT1—hematologic cancer	5.43e-06	8.92e-06	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—IL6—hematologic cancer	5.37e-06	8.83e-06	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—EP300—hematologic cancer	5.3e-06	8.72e-06	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—HRAS—hematologic cancer	5.18e-06	8.52e-06	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—SRC—hematologic cancer	5.16e-06	8.48e-06	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—VEGFA—hematologic cancer	5.02e-06	8.26e-06	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—STAT3—hematologic cancer	4.97e-06	8.17e-06	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—NRAS—hematologic cancer	4.96e-06	8.15e-06	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—IL6—hematologic cancer	4.96e-06	8.15e-06	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—AKT1—hematologic cancer	4.96e-06	8.15e-06	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Gene Expression—AKT1—hematologic cancer	4.93e-06	8.1e-06	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—MAPK3—hematologic cancer	4.75e-06	7.81e-06	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Metabolism—PIK3CA—hematologic cancer	4.69e-06	7.71e-06	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—MYC—hematologic cancer	4.62e-06	7.6e-06	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—TGFB1—hematologic cancer	4.61e-06	7.58e-06	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—AKT1—hematologic cancer	4.58e-06	7.52e-06	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—KRAS—hematologic cancer	4.27e-06	7.02e-06	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—PIK3CA—hematologic cancer	3.92e-06	6.45e-06	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Metabolism—AKT1—hematologic cancer	3.83e-06	6.3e-06	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—TP53—hematologic cancer	3.8e-06	6.24e-06	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—HRAS—hematologic cancer	3.63e-06	5.97e-06	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—IL6—hematologic cancer	3.47e-06	5.71e-06	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—AKT1—hematologic cancer	3.21e-06	5.27e-06	CbGpPWpGaD
